Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Public ClinicalTrials.gov record NCT04541108. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 0 Master Protocol Using the CIVO® Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients With Solid Tumors
Study identification
- NCT ID
- NCT04541108
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- Presage Biosciences
- Industry
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- Rilvegostomig Biological
- Sabestomig Biological
- Volrustomig Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 25, 2021
- Primary completion
- Nov 30, 2031
- Completion
- Nov 30, 2031
- Last update posted
- Apr 17, 2024
2021 – 2031
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Davis | Sacramento | California | 95817 | Recruiting |
| Emory Winship Cancer Institute | Atlanta | Georgia | 30308 | Recruiting |
| LSU Health Sciences Center - Shreveport | Shreveport | Louisiana | 71115 | Recruiting |
| Montefiore Medical Center | The Bronx | New York | 10467 | Recruiting |
| University of North Carolina | Chapel Hill | North Carolina | 27599 | Recruiting |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | Withdrawn |
| UC Health | Cincinnati | Ohio | 45229 | Completed |
| Oregon Health & Science University (OHSU) | Portland | Oregon | 97239 | Recruiting |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Sarah Cannon Research Institute | Charleston | South Carolina | 29406 | Recruiting |
| UT Health | Houston | Texas | 77030 | Recruiting |
| University of Washington | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04541108, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 17, 2024 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04541108 live on ClinicalTrials.gov.